| Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea (NCT07577661) | Brigham and Women's Hospital | 2026-06-01 |
| Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer (NCT06616155) | University of Michigan Rogel Cancer Center | 2026-06-01 |
| Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac (NCT07457307) | NYU Langone Health | 2026-06-01 |
| Intervention of CAR-T Against Cervical Cancer (NCT03356795) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) (NCT07488923) | Moonlight Bio, Inc | 2026-06-01 |
| A Study of CDX-622 in Participants With Mild to Moderate Asthma (NCT07330778) | Celldex Therapeutics | 2026-06-01 |
| ITX24-01 in Adult Male and Female Patients With Select Types of Severe Chronic Neck- and Lower Back Pain (NCT07520240) | Interventional AnalgesiX Inc. | 2026-06-01 |
| CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML (NCT07347418) | University of Colorado, Denver | 2026-06-01 |
| Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas (NCT03356782) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| GD2/PSMA Bi-specific CAR-T Cell Therapy (NCT05437315) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors (NCT07383506) | Cogent Biosciences, Inc. | 2026-06-01 |
| CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy (NCT07443826) | Unlimited Biotechnology LLC | 2026-06-01 |
| Use of Biocompatible Thermoplastic Impregnated With Vancomycin as a Temporary Orthopedic Spacer (NCT07031999) | Hospital Universitario Evangelico de Curitiba | 2026-06-01 |
| RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis (NCT07006805) | Cabaletta Bio | 2026-06-01 |
| Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer (NCT07636798) | West China Hospital | 2026-06-01 |
| 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma (NCT07590336) | Peking Union Medical College Hospital | 2026-06-01 |
| CD19/22 Bi-specific CAR-T Cell Therapy (NCT05432882) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors (NCT07408258) | OncoC4, Inc. | 2026-06-01 |
| A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations (NCT06287918) | 3H (Suzhou) Pharmaceuticals Co., Ltd. | 2026-06-01 |
| Antigen-specific T Cells Against Lung Cancer (NCT03356808) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fasting Conditions (NCT07643220) | AJU Pharm Co., Ltd. | 2026-06-01 |
| A Phase I Study of HW241045 in Healthy Subjects (NCT07593690) | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | 2026-06-01 |
| On Track for Wellness (OTW) Stepped Wedge Cluster Randomized Trial (NCT07387705) | University of Illinois at Chicago | 2026-06-01 |
| Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency (NCT07385846) | Jennifer Leddon | 2026-06-01 |
| Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections (NCT03159364) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 (NCT04432649) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Healthy Participants Randomized, Double-blind, Placebo-controlled, Phase Ⅰ (NCT07640438) | First Affiliated Hospital of Zhejiang University | 2026-06-01 |
| Assessing the Impact of Unnecessary Antibiotic Treatment on the Development of Appropriate Adaptive Immune Responses in Malnourished Bangladeshi Infants (NCT07615842) | University of Virginia | 2026-06-01 |
| CAR-T Cells Targeting Autoimmune Diseases (NCT05459870) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma (NCT07688187) | PeptiDream Inc. | 2026-06-01 |
| Topical Insulin for Glaucoma (TING2) (NCT07619482) | Stanford University | 2026-06-01 |
| HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006) (NCT07441889) | University of Virginia | 2026-06-01 |
| A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. (NCT07559929) | Hangzhou DAC Biotechnology Co., Ltd. | 2026-06-01 |
| Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT07532148) | Chong Kun Dang Pharmaceutical | 2026-06-01 |
| GD2/CD56 Bi-specific CAR-T Cell Therapy (NCT05437328) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| 4SCAR19U T Cells Targeting B Cell Malignancies (NCT05995015) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer (NCT07587034) | Shanghai Zhongshan Hospital | 2026-06-01 |
| Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC (NCT07523464) | Anhui Provincial Hospital | 2026-06-01 |
| External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL (NCT07528352) | University of Utah | 2026-06-01 |
| CD19/70 Bi-specific CAR-T Cell Therapy (NCT05436496) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Evaluation of the Safety and Preliminary Efficacy of Neuroinduced Mesenchymal Stem Cells and Exosome Therapy in Patients With Spinocerebellar Palsy (NCT07467733) | Biocells Medical | 2026-06-01 |
| Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma (NCT07581704) | Christopher Strouse | 2026-06-01 |
| B7-H3.CD28Z.CART in Solid Tumors (NCT07358260) | Robbie Majzner | 2026-06-01 |
| A Clinical Study to Evaluate the Safety of MF1, a New Treatment for Parkinson's Disease-related Disorders (MF1 Study) (NCT07666022) | University of Shizuoka | 2026-06-01 |
| A Multiple Baseline Feasibility Trial of Social Management Training for People With Sex Chromosome Aneuploidies (NCT07718997) | University of Oslo | 2026-06-01 |
| A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies (NCT07503353) | Sheba Medical Center | 2026-06-01 |
| Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL (NCT07643805) | The First Affiliated Hospital with Nanjing Medical University | 2026-06-01 |
| Human Mass Balance Study of [¹⁴C]HRS-1893 (NCT07656779) | Shandong Suncadia Medicine Co., Ltd. | 2026-06-01 |
| A Study of IDP-001 in Advanced or Metastatic Solid Tumors (NCT07602842) | InduPro, Inc. | 2026-06-01 |
| Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer (NCT07488884) | ImmunityBio, Inc. | 2026-06-01 |
| Phase I Study of FXS0683 in the Treatment of Blood Tumors (NCT07616089) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2026-06-01 |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies (NCT04033302) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Treatment of Recurrent/Metastatic Head and Neck Cancer (NCT07601204) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2026-06-01 |
| Subconjunctival Humira for Boston Keratoprosthesis (NCT06926478) | Massachusetts Eye and Ear Infirmary | 2026-06-01 |
| CD19/79b Bi-specific CAR-T Cell Therapy (NCT05436509) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| A Safety Study of Contralateral Eye Dosing of VGR-R01 in Participants With Bietti's Crystalline Dystrophy (BCD) (NCT07586306) | Shanghai Vitalgen BioPharma Co., Ltd. | 2026-06-01 |
| Fecal Microbiota Transplantation for Elderly Patients With HFpEF: A Randomized Controlled Trial (NCT07628777) | The First Affiliated Hospital of Air Force Medicial University | 2026-06-01 |
| Engineered Immune Effectors Against Ovarian Cancer (NCT03362606) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| A Clinical Study Comparing the Bioavailability of HRS-2189 Tablets (NCT07639905) | Shandong Suncadia Medicine Co., Ltd. | 2026-06-01 |
| 4SCAR-CD44v6 T Cell Therapy Targeting Cancer (NCT04427449) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of KH607 in Healthy Chinese Participants (NCT07634874) | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | 2026-06-01 |
| Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer (NCT07484022) | Generate Biomedicines | 2026-06-01 |
| Intraperitoneal Irrigation of Ondansteron in Combination With Lidocaine in Acute Postoperative Pain (NCT07706348) | Assiut University | 2026-06-01 |
| A Phase I Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HS-10522 in Healthy Chinese Participants and Chinese Participants With Mild Hypertension (NCT07609875) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-06-01 |
| A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations (NCT07619001) | Akeso | 2026-06-01 |
| Escalating Doses of Memantine in Down Syndrome (MEDS-123) (NCT07531940) | University Hospitals Cleveland Medical Center | 2026-06-01 |
| R-2487 in Patients With Sjogren's Syndrome (SS) (NCT06297213) | Rise Therapeutics LLC | 2026-06-01 |
| A Study of Psychedelics in Healthy Older Adults With Low Well-being (NCT07386730) | Jennifer Mitchell | 2026-06-01 |
| Cannabidiol Oil for Treatment-Resistant Major Depression (NCT07696871) | Universidade do Sul de Santa Catarina | 2026-06-01 |
| Effects of Sustained-release Oral Sodium Nitrite on Postoperative Pain and Recovery Following Total Knee Arthroplasty (NCT05893160) | University of Alabama at Birmingham | 2026-06-01 |
| Pharmacokinetics and Placental Transfer of Caffeine (NCT07570121) | Indiana University | 2026-06-01 |
| Phase 1 Trial to Evaluate 150 mg Subcutaneous CIT-013 (NCT07499908) | Citryll BV | 2026-05-31 |
| Immune Modulatory DC Vaccine Against Brain Tumor (NCT03914768) | Shenzhen Geno-Immune Medical Institute | 2026-05-31 |
| Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TVAX-028 in the Treatment of Chronic Hepatitis B (NCT07673068) | Grand Theravac Life Sciences (Nanjing) Co., Ltd. | 2026-05-31 |
| TGD001 Treatment in Thrombotic Microangiopathies (NCT07459114) | TargED Biopharmaceuticals B.V. | 2026-05-31 |
| Safety, Tolerability, and Pharmacokinetic Evaluation of ADB116 for Injection (NCT07729839) | Jiangsu Aidea Pharmaceutical Group Co., Ltd. | 2026-05-31 |
| Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours (NCT07594028) | Sinocelltech Ltd. | 2026-05-30 |
| FAK Inhibitor in Patients With Advanced Solid Tumors (NCT07596381) | InxMed (Shanghai) Co., Ltd. | 2026-05-30 |
| The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease (NCT07457125) | Xuanwu Hospital, Beijing | 2026-05-30 |
| Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors (NCT07584499) | Sun Yat-sen University | 2026-05-30 |
| Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT07601607) | Sun Yat-sen University | 2026-05-30 |
| Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients (NCT07371338) | Innopeutics Corporation | 2026-05-30 |
| Recombinant Human Interleukin-7 (JL18008) for the Treatment of HIV-Infected Immunological Non-Responders (NCT07443228) | Jecho Biopharmaceuticals Co., Ltd. | 2026-05-30 |
| Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B (NCT07589400) | Xiamen Amoytop Biotech Co., Ltd. | 2026-05-30 |
| A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT07570017) | Guangzhou Lupeng Pharmaceutical Company LTD. | 2026-05-30 |
| JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC (NCT07582822) | Biotech Pharmaceutical Co., Ltd. | 2026-05-30 |
| Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors (NCT07583914) | West China Hospital | 2026-05-30 |
| Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas (NCT07478848) | Abramson Cancer Center at Penn Medicine | 2026-05-29 |
| A Study to Learn About How Safe BAY3389934 is and How it Affects Blood Clotting When Given Alone or With Aspirin in Healthy Participants (NCT07652723) | Bayer | 2026-05-29 |
| Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events (NCT07607587) | Novo Nordisk A/S | 2026-05-29 |
| Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD (NCT06991361) | Leslie Kean | 2026-05-29 |
| SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors (NCT07622225) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-05-29 |
| A Phase 1 Clinical Study in Healthy Participants (NCT07584876) | Shanghai Argo Biopharmaceutical Co., Ltd. | 2026-05-29 |
| A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors (NCT07583316) | Corregene Biotechnology Co., Ltd | 2026-05-29 |
| A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379 (NCT07712718) | Mirum Pharmaceuticals, Inc. | 2026-05-29 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (NCT06965114) | National Cancer Institute (NCI) | 2026-05-29 |
| Quercetin Dyskeratosis Congenita (DC)/Telomere Biology Disorders (TBD) (NCT07628972) | Children's Hospital Medical Center, Cincinnati | 2026-05-29 |
| A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease (NCT07559396) | Incyte Corporation | 2026-05-29 |
| A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation. (NCT07456046) | D3 Bio (Wuxi) Co., Ltd | 2026-05-29 |
| AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer (NCT07619313) | Jonsson Comprehensive Cancer Center | 2026-05-29 |